Furoxan nitric oxide donor coupled chrysin derivatives: synthesis and vasculoprotection.
A series of furoxan-based nitric oxide-releasing chrysin derivatives were synthesized. Pharmacological assays indicated that all chrysin derivatives exhibited in vitro inhibitory activities against aldose reductase and advanced glycation end-product formation. Some chrysin derivatives were also found to increase the glucose consumption of HepG2 cells. Furthermore, the compounds released a low amount of NO in the presence of L-cysteine (range from 0.20% to 1.89%). These hybrid furoxan-based NO donor chrysin derivatives offer a mutual prodrug design concept for the development of therapeutic or preventive agents for vascular complications due to diabetes.
Department of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha 410078, China.
Xiao-Qing
XQ
Zou
Sheng-Ming
SM
Peng
Chang-Ping
CP
Hu
Li-Feng
LF
Tan
Han-Wu
HW
Deng
Yuan-Jian
YJ
Li
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors / Q000378:metabolism; D003545:Cysteine / Q000378:metabolism; D005419:Flavonoids / Q000138:chemical synthesis / Q000737:chemistry* / Q000627:therapeutic use; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors / Q000378:metabolism; D056945:Hep G2 Cells; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism*; D010069:Oxadiazoles / Q000737:chemistry*; D014652:Vascular Diseases / Q000517:prevention & control*
C528141:1,2,5-oxadiazole 2-oxide; D005419:Flavonoids; D017127:Glycation End Products, Advanced; D010069:Oxadiazoles; D009569:Nitric Oxide; C043561:chrysin; D000449:Aldehyde Reductase; D003545:Cysteine